Comparison of the Effect of Exenatide Versus Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione

Comparison of the Effect of Exenatide vs. Sitagliptin on 24-hour Average Glucose in Patients With Type 2 Diabetes on Metformin or a Thiazolidinedione

This study is designed to compare the short-term effects and mechanisms of action of exenatide with those of sitagliptin when either is added to an oral agent(metformin or a thiazolidinedione [TZD]) in adult patients with type 2 diabetes mellitus(T2DM) with inadequate glycemic control.

Study Overview

• Status: Completed
• Conditions: Type 2 Diabetes Mellitus
• Intervention / Treatment: Drug: exenatide; Drug: sitagliptin; Drug: placebo; Drug: placebo

• Study Type: Interventional
• Enrollment (Actual): 83
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • Texas
    • San Antonio, Texas, United States
      • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Have type 2 diabetes
• Has HbA1c 7.0% to 11.0%, at or within 4 weeks prior to Visit 1.
• Have a fasting glucose concentration <280 mg/dL at Visit 1
• Have been treated with a stable dose of immediate or extended release metformin for at least 60 days prior to screening OR TZD (rosiglitazone or pioglitazone) for at least 120 days prior to screening.
• Are between 18 and 70 years of age, inclusive.
• Have body mass index ≥25 kg/m2 and ≤45 kg/m2.
• Have a history of stable body weight (not varying by >10% for at least 3 months prior to screening).
• Can swallow oral study drug capsule, without splitting or crushing.

Exclusion Criteria:

• Female patients of childbearing potential (not surgically sterilized and between menarche and 1 year postmenopause) who meet any of the following criteria:

  • Are breastfeeding.
  • Test positive for pregnancy at the time of screening.
  • Intend to become pregnant during the study.
  • Have not practiced a reliable method of birth control (for example, use of oral contraceptives or Norplant®; diaphragms with contraceptive jelly; cervical caps with contraceptive jelly; condoms with contraceptive foam; intrauterine devices; partner with vasectomy; or abstinence) for 3 months prior to screening.

• Treated with any of the following medications:

  • Insulin, exenatide, pramlintide, sulfonylureas or meglitinides within 3 months of screening
  • Alpha-glucosidase inhibitor within 2 months of screening.
  • Drugs that directly affect gastrointestinal motility, including, but not limited to metoclopramide, cisapride, and chronic macrolide antibiotics.
  • Use of a drug for weight loss (for example, prescription drugs such as orlistat, sibutramine, phentermine, or similar over-the-counter medications) within 3 months prior to Visit 1.
  • Systemic corticosteroids by oral, intravenous, or intramuscular route within 2 months of screening.
• Have a history of renal transplantation or are currently receiving renal dialysis.
• Have obvious clinical signs or symptoms of liver disease or acute or chronic hepatitis.
• Have known active proliferative retinopathy or macular edema expected to need treatment with focal photocoagulation within 3 months.
• Have an active or untreated malignancy, or have been in remission from clinically significant malignancy (other than basal cell or squamous cell skin cancer, in situ carcinomas of the cervix, or in situ prostate cancer) for less than 5 years.
• Have had organ transplantation.
• Have received GLP-1 analogs other than exenatide or DPP-4 inhibitors within the previous 3 months.
• Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Crossover Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Sequence A	Drug: exenatide; subcutaneous injection (5mcg or 10mcg), twice a day; Other Names: Byetta; Drug: sitagliptin; oral administration (100mg), once a day in the morning; Other Names: Januvia; Drug: placebo; subcutaneous injection (5mcg or 10mcg), twice a day; Drug: placebo; oral administration (100mg), once a day in the morning
Experimental: Sequence B	Drug: exenatide; subcutaneous injection (5mcg or 10mcg), twice a day; Other Names: Byetta; Drug: sitagliptin; oral administration (100mg), once a day in the morning; Other Names: Januvia; Drug: placebo; subcutaneous injection (5mcg or 10mcg), twice a day; Drug: placebo; oral administration (100mg), once a day in the morning

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Time-averaged Glucose During a 24 Hour Period	Change in time-averaged glucose during a 24-hour period from baseline to endpoint (i.e., time-averaged glucose over 24 hours at endpoint minus time-averaged glucose over 24 hours at baseline).	baseline and 8 Weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Two-hour Postprandial Glucose After the Morning Meal	Change in 2 hour post-prandial glucose after the morning meal from baseline to endpoint (i.e., glucose level 2 hours after the morning meal at baseline minus glucose level 2 hours after the morning meal at endpoint)	baseline and 8 Weeks
Change in Fasting Blood Glucose After the Morning Meal	Change in fasting blood glucose after the morning meal from baseline to endpoint (i.e., fasting blood glucose after the morning meal at baseline minus fasting blood glucose after the morning meal at endpoint)	baseline and 8 Weeks
Change in Postprandial Glucagon Area Under the Concentration-time Curve (AUC) After the Morning Meal	Change in Postprandial Glucagon AUC after the morning meal (t=0 to 4 hours) (i.e., Glucagon AUC over the first 4 hours following the morning meal at baseline minus glucagon AUC over the first 4 hours following the morning meal at endpoint)	baseline and 8 Weeks
Change in Postprandial Glucagon AUC Excursion After the Morning Meal	Change in postprandial glucagon AUC excursion after the morning meal (t=0 to 4 hours) (i.e., glucagon AUC excursion for 4 hours following the morning meal at baseline minus glucagon AUC excursion for 4 hours following the morning meal at endpoint)	baseline and 8 Weeks
Change in Postprandial Triglyceride AUC After the Morning Meal	Change in postprandial triglyceride AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial triglyceride AUC after the morning meal at baseline minus postprandial triglyceride AUC after the morning meal at endpoint)	baseline and 8 Weeks
Change in Postprandial Triglyceride AUC Excursion After the Morning Meal	Change in postprandial triglyceride AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial triglyceride AUC excursion after the morning meal at baseline minus postprandial triglyceride AUC excursion after the morning meal at endpoint)	baseline and 8 Weeks
Change in Postprandial C-peptide AUC After the Morning Meal	Change in postprandial C-peptide AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial C-peptide AUC after the morning meal at baseline minus postprandial C-peptide AUC after the morning meal at endpoint)	baseline and 8 Weeks
Change in Postprandial C-peptide AUC Excursion After the Morning Meal	Change in Postprandial C-peptide AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial C-peptide AUC excursion after the morning meal at baseline minus postprandial C-peptide AUC excursion after the morning meal at endpoint)	baseline and 8 Weeks
Change in Postprandial Insulin AUC After the Morning Meal	Change in postprandial insulin AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial insulin AUC after the morning meal at baseline minus postprandial insulin AUC after the morning meal at endpoint)	baseline and 8 Weeks
Change in Postprandial Insulin AUC Excursion After the Morning Meal	Change in Postprandial insulin AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial insulin AUC excursion after the morning meal at baseline minus postprandial insulin AUC excursion after the morning meal at endpoint)	baseline and 8 Weeks
Change in Postprandial Active GLP-1 AUC After the Morning Meal	Change in Postprandial active GLP-1 AUC after the morning meal (t=0 to 4 hours) (i.e., postprandial active GLP-1 AUC after the morning meal at baseline minus postprandial active GLP-1 AUC after the morning meal at endpoint)	baseline and 8 Weeks
Change in Postprandial Active GLP-1 AUC Excursion After the Monrning Meal	Change in Postprandial active GLP-1 AUC excursion after the morning meal (t=0 to 4 hours) (i.e., postprandial active GLP-1 AUC excursion after the morning meal at baseline minus postprandial active GLP-1 AUC excursion after the morning meals at endpoint)	baseline and 8 Weeks
Percentage of Patients Experiencing Hypoglycemia (Baseline to Week 4)	Percentage of patients experiencing minor hypoglycemia with a confirmed glucose <54mg/dL	4 Weeks
Episodes of Hypoglycemia (Baseline to Week 4)	Number of episodes of hypoglycemia experienced during the first 4 weeks of the study	4 weeks
Percentage of Patients Experiencing Hypoglycemia (Week 4 to Week 8)	Percentage of patients experiencing minor hypoglycemia with a confirmed glucose <54mg/dL	8 weeks
Episodes of Hypoglycemia (Week 4 to Week 8)	Number of episodes of hypoglycemia experienced between week 4 and week 8 of the study	8 weeks
Percentage of Patients Experiencing Hypoglycemia (Overall)	Percentage of patients experiencing minor hypoglycemia with a confirmed glucose <54mg/dL	4 weeks and 8 weeks
Episodes of Hypoglycemia (Overall)	Number of episodes of hypoglycemia experienced overall during the study	4 weeks and 8 weeks

Collaborators and Investigators

• Sponsor: AstraZeneca
• Collaborators: Eli Lilly and Company

Study record dates

Study Major Dates

• Study Start: August 1, 2008
• Primary Completion (Actual): October 1, 2009
• Study Completion (Actual): October 1, 2009

Study Registration Dates

• First Submitted: August 4, 2008
• First Submitted That Met QC Criteria: August 6, 2008
• First Posted (Estimate): August 7, 2008

Study Record Updates

• Last Update Posted (Estimate): April 9, 2015
• Last Update Submitted That Met QC Criteria: March 20, 2015
• Last Verified: March 1, 2015

More Information

Terms related to this study

• Keywords: diabetes; metformin; thiazolidinedione; exenatide; Lilly; Amylin; sitagliptin
• Additional Relevant MeSH Terms: Glucose Metabolism Disorders; Metabolic Diseases; Endocrine System Diseases; Diabetes Mellitus; Diabetes Mellitus, Type 2; Hypoglycemic Agents; Physiological Effects of Drugs; Molecular Mechanisms of Pharmacological Action; Enzyme Inhibitors; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Protease Inhibitors; Anti-Obesity Agents; Incretins; Dipeptidyl-Peptidase IV Inhibitors; Sitagliptin Phosphate; Exenatide
• Other Study ID Numbers: H8O-US-GWCV